Luminary Therapeutics

Jeff Liter, President and CEO 

Oct. 12 | 11:00am | Oxford Biomedica Ballroom 

Minneapolis, MN 


In-person Presentation 

Luminary Therapeutics is a clinical-stage cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Our novel ligand-based CAR is designed to bind three targets and is set to enter the clinic in Q3 2022. Additionally, we have an allogeneic platform based on gamma delta cells. Luminary was founded by the team from B-MoGen that achieved a successful 5x exit in only three years. We are seeking Series A financing with venture firms or strategic partners to support our first clinical trial and development of our disruptive U-Receptor that can modulate antigen specificity. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions